Satoko Ito, MD, PhD
Postdoctoral FellowAbout
Research
Publications
2026
Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding
Wang D, Sra M, Ito S, Ng D, Glaeser-Khan S, Wang D, Hirniak S, Lee A, Cuker A, Goshua G. Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding. Blood Advances 2026, 10: 1508-1517. PMID: 41504430, PMCID: PMC12952766, DOI: 10.1182/bloodadvances.2025018315.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingIV iron dextranIron deficiency anemiaQuality-adjusted life yearsOral ferrous sulfateFirst-line treatmentIron dextranOral ironMenstrual bleedingCost-effective treatmentIron deficiencyFrequent gastrointestinal side effectsIV iron sucroseOral iron therapyFirst-line therapyQuality-adjusted life-year benefitsFirst-line optionIncremental cost-effectiveness ratioGastrointestinal side effectsCohort of womenCost-effectiveness ratioIron therapyIron sucroseIV ironTreatment delay
2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025, 9: 6237-6245. PMID: 40795232, PMCID: PMC12744270, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilityUnderstanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind
Goshua G, Wang D, Ito S, Ng D, Pandya A. Understanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind. Journal Of The American College Of Cardiology 2025, 86: 2130-2132. PMID: 41298026, DOI: 10.1016/j.jacc.2025.09.1574.Peer-Reviewed Original ResearchAnchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A
Ito S, Sra M, Goshua G. Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A. PharmacoEconomics 2025, 43: 761-764. PMID: 40410545, PMCID: PMC12167127, DOI: 10.1007/s40273-025-01508-w.Peer-Reviewed Original ResearchCost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening
Ito S, Xicola R, Sra M, Potnis K, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz H, Llor X, Goshua G. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clinical Gastroenterology And Hepatology 2025, 23: 2328-2338.e9. PMID: 40315972, PMCID: PMC12354148, DOI: 10.1016/j.cgh.2025.03.006.Peer-Reviewed Original ResearchLynch syndromeIncremental cost-effectiveness ratioGermline testingColorectal cancerProspective Lynch Syndrome DatabaseColorectal cancer probandsNational Cancer Institute's SurveillancePre-/post-interventionPreventing cancer incidenceLynch syndrome screeningEnd Results ProgramCost-effective interventionHealth system perspectiveCost-effectiveCancer incidenceQuality-adjusted life expectancyInstitute's SurveillanceResults ProgramProspective interventionStandard-of-careCost-effectiveness ratioLS testingCohort studyGenetic testingPrimary outcomeProphylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.
Ito S, Potnis K, Harvey J, Sra M, Bewersdorf J, Bona R, Krumholz H, Cuker A, Pandya A, Goshua G. Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2025, 178: 819-828. PMID: 40258278, PMCID: PMC12170149, DOI: 10.7326/annals-24-02749.Peer-Reviewed Original ResearchConceptsEquity weightsSevere hemophilia AInequality aversion parameterFactor VIIIHemophilia AAversion parameterCost-effectiveness analysisEquity standardsCost-effectiveness of prophylaxisTime horizonOnce-weekly prophylaxisPriceAnnualized bleeding rateIncremental cost-effectiveness ratioFactor VIII prophylaxisScenario analysisCost-effectiveness ratioUnited StatesLifetime QALYsBleeding rateProphylaxisNational Institutes of HealthCost-effectiveInstitutes of HealthAlfaCost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women
Wang D, Sra M, Glaeser‐Khan S, Wang D, Moshashaian‐Asl R, Ito S, Cuker A, Goshua G. Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women. American Journal Of Hematology 2025, 100: 1132-1140. PMID: 40235279, PMCID: PMC12146817, DOI: 10.1002/ajh.27686.Peer-Reviewed Original ResearchConceptsWomen of reproductive ageFerritin thresholdIron deficiencyReproductive ageCost-effective interventionUS health system perspectiveNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyIncremental cost-effectiveness ratioCost-effectiveness of screeningTreatment of IDNutrition Examination SurveyMarkov cohort modelCost-effectiveness ratioProbabilistic sensitivity analysesHealth system perspectiveReproductive-agePrimary outcomeExamination SurveyLifetime QALYsDisability-adjusted life yearsIron repletionBase-caseFerritinID prevalenceUsing Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency
Goshua G, Varghese M, Ito S, Pandya A. Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency. Journal Of The American College Of Cardiology 2025, 85: 1376-1378. PMID: 40139895, PMCID: PMC12039621, DOI: 10.1016/j.jacc.2025.01.005.Peer-Reviewed Original Research
2024
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomeCancer research is not correlated with driver gene mutation burdens
Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, PMCID: PMC12092095, DOI: 10.1016/j.medj.2024.05.013.Peer-Reviewed Original ResearchCancer patient populationCancer researchCancer research effortsResearch allocation decisionsNational InstitutePatient populationResearch fundingBurdenBurden of mutationsFunding decisionsCancerGenetic driversGene mutation burdenFunding amountFundingGenetic drivers of cancerAllocation decisionsCancer-associated genesEpidemiologyDrivers of cancerMutational burdenBaselineEffortsFactorsBalance of priorities
Academic Achievements & Community Involvement
News
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- December 06, 2023
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
- May 30, 2023
Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease
Get In Touch
Contacts
Email